Emmaus Life Sciences continues to expand the reach of Endari® (L-glutamine oral powder), its FDA-approved therapy for reducing acute complications of sickle cell disease (SCD). Currently available in the U.S., Israel, and Gulf Cooperation Council (GCC) countries, the company is actively pursuing regulatory approvals in new markets, including Saudi Arabia, where a final decision from the Saudi Food & Drug Authority (SFDA) is pending. Endari® remains a critical option for SCD patients, particularly in regions with limited treatment access. Early-access programs in France, the Netherlands, and the Kingdom of Saudi Arabia ensure patients can receive the therapy while awaiting full approvals. The drug’s mechanism has demonstrated real-world benefits, helping to lower pain crisis frequency in adults and children (5+ years).

OxyDial supports Emmaus’ efforts to bring Endari® to more patients worldwide. As the SCD treatment landscape grows, maintaining affordable, accessible options remains crucial for improving long-term outcomes.

Read more: https://www.nasdaq.com/press-release/emmaus-life-sciences-reports-quarterly-financial-results-2025-05-15

#SickleCellDisease #SCD #Endari #RareDisease #GlobalHealth #PatientAccess #Hemoglobinopathy #SickleCellAwareness #OrphanDrug #Biopharma #FDAApproved #MedicalInnovation #HealthcareEquity #ChronicPain #PediatricHealth #DrugDevelopment #OxyDial